Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF),4,5 which plays a key role in tumor growth and metastasis through the promotion of angiogenesis and neovascularization.6 This evidence concerns the gene VEGFA and neoplasm.